Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 1997, for Sheffield Pharmaceuticals, Inc. (formerly Sheffield Medical Technologies, Inc.). The company is classified as a development stage enterprise focused on biotechnology research, specifically in pulmonary delivery systems (MSI), HIV/AIDS vaccines, and prostate cancer technologies. The company has generated minimal operating revenue and relies on external financing to fund operations.
Key Financial Metrics
| Metric | Three Months Ended 9/30/97 | Nine Months Ended 9/30/97 | Inception to 9/30/97 |
|---|---|---|---|
| Total Revenue | $9,391 | $49,363 | $956,276 |
| Net Loss | $(1,888,836) | $(7,978,323) | $(34,566,975) |
| Research & Development Expenses | $570,170 | $3,283,632 | $18,806,830 |
| Cash and Cash Equivalents | $1,005,106 (End of Period) | Decreased $974,765 from beginning of nine-month period | |
| Convertible Debentures | $1,750,000 (Issued Sept 22, 1997) | ||
| Preferred Stock Issued | $3,212,136 (Series A, issued Feb 1997) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue for the three months ended September 30, 1997, was $9,391, a significant decrease from $555,275 in the same period in 1996. The 1996 figure included $500,000 in sub-license revenue which did not recur in 1997.
- Expense Reduction: Total operating expenses decreased to $1,898,227 for the quarter ended September 30, 1997, from $2,131,571 in the prior year quarter. This was driven by lower consulting fees and reduced R&D spending.
- Financing Activity: The company raised $1.75 million via 6% Convertible Subordinated Debentures in September 1997 and $3.5 million via Series A Preferred Stock in February 1997. These proceeds offset the cash burn from operations.
- Asset Liquidation: The company sold marketable securities, resulting in a loss of approximately $300,000 recorded in the nine-month period.
Guidance, Outlook, and Risks
- Future Funding Needs: Management projects approximately $7.8 million in additional funding requirements over the next 12 months for clinical and laboratory R&D. The majority ($7.5 million) is allocated to the Multi-Dose Solution Inhaler (MSI) project.
- Liquidity Risk: The company explicitly states its ability to continue as a going concern for the next 12 months is dependent on obtaining additional financing through equity or debt offerings. There is no assurance such financing will be available.
- Contractual Obligations: The company entered into an exclusive license agreement with Siemens A.G. for the MSI technology, requiring a $1.1 million upfront payment (made in April 1997) and future payments of DM 2.0 million in 1998 and 1999.
- Forward-Looking Statements: The filing contains forward-looking statements regarding technology development and financing, which are subject to significant risks and uncertainties.
Investor Verification Checklist
- Verify the status of ongoing negotiations for the proposed bridge loans or security financings mentioned in the liquidity section.
- Confirm the timeline and budget for the $7.8 million projected R&D spend, specifically the $7.5 million allocated to the MSI project.
- Review the terms of the Siemens A.G. license agreement regarding the DM 2.0 million future payments and currency exchange risks.
- Assess the dilution impact of the outstanding 6% Convertible Debentures ($1.75 million) and Series A Preferred Stock.
- Monitor the company's cash burn rate against the current cash balance of ~$1 million to determine the runway before additional capital is required.